MDR1 gene expression in primary colorectal carcinomas. by Pirker, R. et al.
Br. J. Cancer (1993), 68, 691 694 © Macmillan Press Ltd., 1993~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MDR1 gene expression in primary colorectal carcinomas
R. Pirkerl, J. Wallnerl, A. Gsur', M. G 'tzl', S. Zdchbauerl, W. Scheithauerl & D. Depisch2
'Clinicfor Internal Medicine I, Department ofOncology, University of Vienna Medical School, 1090 Vienna, and 2Department of
Surgery, General Hospital, 2700 Wr. Neustadt, Austria.
Summary The expression of the MDRI gene, a multidrug resistance gene, was prospectively determined in
113 primary colorectal carcinoma specimens and correlated with clinical data including survival durations of
the patients. MDR1 RNA was detected in 65% of the carcinomas. No expression of the MDR2 gene was
seen. MDR1 gene expression was independent of age and sex of the patients, size and histologic grading of the
tumour, lymph node involvement and distant metastasis. Kaplan-Meier analysis revealed that the durations of
both relapse-free survival and overall survival were not different between patients with MDRI RNA positive
tumours and those with MDR1 RNA negative tumours.
Multidrug resistance, an important type of drug resistance in
tumour cell lines, is due to the expression of the MDR1 gene
(Pastan & Gottesman, 1987; Riordan et al., 1985; Roninson
et al., 1986). This gene codes for P-glycoprotein, a 170 kD
transmembrane protein, which functions as an energy-depen-
dent drug efflux pump for hydrophobic natural compounds
including certain cytotoxic drugs (e.g. anthracyclines, Vinca
alkaloids) (Pastan & Gottesman, 1987; 1988). P-glycoprotein
is expressed in various normal tissues including normal colon
epithelium, where it most likely functions as a transport
protein, albeit its physiological ligands remain to be deter-
mined.
The previous observation of MDR1 gene expression in nor-
mal and malignant tissues of the colon (Thiebaut et al., 1987;
Fojo et al., 1987a) prompted us to prospectively determine the
clinical significance of MDR1 gene expression in colorectal
carcinomas. One objective was to evaluate both frequency and
intensity of MDR1 gene expression on a large study popula-
tion in order to assess whether MDR1 gene expression might
be considered as one of the mechanisms involved in the drug
resistance of these tumours, which often are intrinsically resis-
tant to cytotoxic drugs (Cohen et al., 1989). Another major
goal of our study was to assess the association of MDR1
RNA transcripts with other clinical parameters. In particular,
we wanted to determine the relationship between MDR1
gene expression of the carcinomas and the durations of both
disease-free and overall survival of the patients in order to
determine whether the multidrug resistance phenotype is
associated with a more aggressive disease. The possibility of
such an association was previously raised by Weinstein et al.
(1990; 1991) who found that P-glycoprotein expression at the
leading edge of the tumours was associated with local
tumour aggressiveness and lymph node metastasis but did
not report whether this association also translated into
different survival durations of the patients. The results of our
study are reported here.
Patients and methods
Tumour specimens
From 1988 to 1991, specimens of colorectal carcinomas were
obtained from 113 patients (58 females, 55 males) who
underwent surgery at the General Hospital of Wr. Neustadt,
Austria. Tumour specimens were immediately frozen and
stored at - 70°C until use.
Cell lines
Drug-sensitive KB-3-1 cells and multidrug-resistant KB-8-5
cells (provided by Dr I. Pastan, NIH, Bethesda, MD, USA)
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were grown as described (Pirker et al., 1991; Wallner et al.,
1991).
Determination ofMDR] gene expression
MDR1 RNA levels of tumour specimens and cell lines were
determined by a slot blot technique as described in detail
elsewhere (Pirker et al., 1991; Wallner et al., 1991). Briefly,
tumour specimens were homogenised in RNAzol (Cinna/
Biotecx Lab. Int. Inc., Friendswood, Texas). Total RNA was
extracted by means of RNAzol as described in the manufac-
turer's manual. The intactness of the RNA was confirmed by
agarose formaldehyde gel electrophoresis. RNA was blotted
onto nylon membrane filters. After prehybridisation, filters
were hybridised with a radio-labelled MDR1 cDNA (probe
SA; provided by Dr Ira Pastan and Dr Michael Gottesman,
National Cancer Institute, Bethesda, MD, USA) in 50%
formamide, 5 x SSC, 20 mM sodium phosphate buffer (pH
6.5), 10% dextran sulfate, 1 x Denhardt's Reagent and
0.2mg ml-' salmon sperm DNA at 42°C for 18-20 h. After
washings, auto-radiographic exposures lasted for 2-5 days
(Figure 1). RNA loading was normalised to actin expression
(Pirker et al., 1991). No expression was seen in drug-sensitive
KB-3-1 cells and an arbitrary value of 30 units (U) was
assigned to the MDR1 RNA expression of 10gg of total
RNA from multidrug-resistant KB-8-5 cells (Goldstein et al.,
1989; Pirker et al., 1991).
Determination ofexpression ofMDR2 RNA
The MDR2 RNA levels were determined by a slot blot
hybridisation, using a human MDR2 (MDR3) probe (40mer,
Pr-1, Oncogene Science), which had been radiolabelled with
gamma- 32P-ATP. Filters were prehybridised overnight at
65°C in 1 M NaCl, 50 mM Tris/HCl buffer (pH 7.5), 5 x Den-
hardt's Reagent, 1% SDS and salmon sperm DNA. Hybrid-
isation was then performed overnight at 65°C in 1 M NaCl,
50 mM Tris/HCl buffer (pH 7.5), 5 x Denhardt's Reagent,
1% SDS, 10% dextran sulfate and salmon sperm DNA.
After washings with 2 x SSC containing 0.1% SDS (5 min at
room temperature; 30 min at 65°C; 5 min at room
temperature), autoradiography was performed.
Survival analysis
Durations of disease-free survival and of overall survival
were estimated according to Kaplan-Meier (1958) in 91 and
103 patients, respectively. Among these evaluable patients, 30
patients with tumour stages II or III, participating in an
adjuvant chemotherapy trial, received postoperative intra-
venous chemotherapy with 5-fluorouracil and leucovorin over
a period of 6 months, supplemented with intraperitoneal
chemotherapy in some cases. The remaining patients had no
further treatment after surgery.
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Table I Expression of the MDRI and MDR2 genes in primary
colorectal carcinomas
No. (%)
MDR] gene
Evaluable tumours 113 (100%)
MDR1 RNA negative tumours 40 (35%)
MDRI RNA positive tumours 73 (65%)
low 32 (28%)
intermediate 26 (23%)
high (>9 U) 15 (13%)
MDR2 gene
Evaluable tumours 98 (100%)
MDR2 RNA negative tumours 98 (100%)
MDR2 RNA positive tumours 0 (0%)
MDR1 and MDR2 RNA expression of primary colorectal
carcinomas were determined by slot blot analysis.
Figure 1 Slot blot analysis for MDR1 RNA. MDR1 RNA
expression (left lane) was determined by slot blot analysis. Actin
expression (right lane) was used to ensure RNA loading and to
correct for different amounts of RNA loaded. MDR1 RNA levels
were negative in drug-sensitive KB-3-1 cells (10 fig RNA; negative
control) and positive in multidrug-resistant KB-8-5 cells (10, 3
and I jig RNA; positive control). The slot at the bottom refers to
a colorectal tumour specimen.
Statistical analysis
Frequencies were tested by chi-square tests. Comparisons of
survival durations between patients with MDR1 RNA posi-
tive tumours and those with MDR1 RNA negative tumours
were done with the Wilcoxon test.
Results
MDR 1 RNA expression of 113 primary colorectal carcin-
omas was determined by slot blot analysis and compared
with the expression of drug-sensitive KB-3-1 cells and 4- to
6-fold multidrug-resistant KB-8-5 cells (Figure 1). MDR1
RNA levels were negative in 40 (35%) and positive in 73
(65%) carcinoma samples (Table I). MDR1 RNA levels were
low, intermediate and high (>9 U) in 32 (28%), 26 (23%)
and 15 (13%) tumour specimens, respectively. To exclude the
possibility that the observed MDR1 transcripts were due to
the expression of the MDR2 gene, which in vitro does not
correlate with the degree of multidrug resistance (Pastan &
Gottesman, 1987), we also measured the MDR2 RNA levels
in 98 tumours. However, no expression of MDR2 RNA was
detected (Table I).
The clinical data of the patients are summarised in Table
II. Histological examination revealed adenocarcinomas in all
cases. MDRI gene expression of the tumours was indepen-
dent of age and sex of the patients, localisation and size of
the primary tumour, tumour infiltration of the lymph nodes,
distant metastases and histologic grading (Table II).
To evaluate whether MDRI gene expression has any
impact on the clinical course of colorectal carcinomas,
Kaplan-Meier analysis of disease-free survival and of overall
survival was performed in 91 and 103 patients, respectively.
The median duration of follow-up of the patients was 2 years
and was not different between patients with MDR1 RNA
positive tumours and those with negative tumours (data not
shown). With respect to the total study population, the dura-
tions of disease-free survival (Figure 2) and of overall survi-
val (Figure 3) were independent of MDR1 RNA expression.
Both among patients with tumour stage II and among
patients with tumour stage III, MDR1 RNA expression had
no impact on the durations of survival (data not shown).
Table II MDR1 RNA levels and clinical data of the patients
MDR] MDR]
all pts. negat. pts. pos. pts. P-value
Number of pts. 113 40 73
Age (yrs)
Median 60 61 59 NS
Range 34-86 40-83 34-86
Sex (flm) 58/55 20/20 38/35
Localisation of the primary tumour
Colon 61% 57% 64% NS
Rectum 38% 43% 36%
Histologic grade
GI 23% 11% 26.5%
G2 72% 89% 66.5% NS
G3 5% - 7%
Primary tumour
Ti 1% 2% -
T2 39% 43% 37%
T3 32% 23% 37% NS
T4 22% 27% 19%
TX 6% 5% 7%
Regional lymph nodes
NO 60% 63% 60%
NI 29% 33% 28%
N2 4% - 5% NS
N3 1% 2% -
NX 6% 2% 7%
Distant metastasis
MO 82% 88% 79%
Ml 12% 7% 14% NS
MX 6% 5% 7%
Patients (%) with adjuvant
chemotherapy 27% 18% 32%
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Figure 2 MDRI RNA expression of colorectal carcinomas and
disease-free survival of the patients. The duration of disease-free
survival was determined according to Kaplan-Meier in 91
patients. The survival duration was not different between patients
with MDR1 RNA positive tumours and those with negative
tumours.
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Figure 3 MDR1 RNA expression of colorectal carcinomas and
overall survival of the patients. The duration of overall survival
of the patients was determined according to Kaplan-Meier in 103
patients. MDR1 RNA expression did not affect the duration of
the overall survival.
When patients with rectal carcinomas and those with colon
carcinomas were separately analysed, also no association
between MDR1 RNA expression and survival durations was
observed (data not shown). Since the percentage of patients
receiving adjuvant chemotherapy was similar for patients
with MDR1 RNA negative tumours as compared to those
with positive tumours (Table II), it is unlikely that our results
were affected by adjuvant chemotherapy. Nevertheless, we
also separately analysed patients with adjuvant chemotherapy
and those without adjuvant chemotherapy. However, in both
groups the durations of disease-free as well as overall sur-
vival of the patients were independent of MDR1 RNA ex-
pression of the tumours (data not shown).
Discussion
Our prospective study demonstrated the expression of the
MDR1 gene in 65% of the primary colorectal carcinomas
examined and thus confirms previous reports on MDR1 gene
expression in these tumours (Pastan & Gottesman, 1987;
Goldstein et al., 1989). We have determined MDR1 gene
expression by measuring MDR1 RNA levels of the tumours,
using a sensitive and semiquantitative slot blot analysis
(Goldstein et al., 1989; Pirker et al., 1991; Wallner et al.,
1991). Because MDR2 RNA expression was not detected in
the tumours, the observed expression of the MDR1 gene did
not result from cross-reactivity of the MDR1 probe with
transcripts of the MDR2 gene. Alternatively, immunohisto-
chemical detection of P-glycoprotein can be applied in order
to demonstrate the expression of the MDR1 gene in tissues
(Thiebaut et al., 1987; Weinstein et al., 1991; Chan et al.,
1990; Wishart et al., 1990). Recently, expression of P-glyco-
protein was seen in 65 out of 95 primary colon carcinomas
(Weinstein et al., 1991), which is consistent with the percen-
tage of MDR1 RNA positive tumours in our study. Whether
MDR1 RNA analysis or immunohistochemical detection of
P-glycoprotein is better suited for clinical purposes, remains
to be determined.
The expression of the MDR1 gene in normal colon epithe-
lium (Thiebaut et al., 1987; Fojo et al., 1987a) suggests that
the MDR1 gene might be expressed predominantly in well
differentiated tumours. However, we did not find a correla-
tion between histologic grade and MDR1 transcripts of the
carcinomas. MDR1 RNA expression was also independent of
localisation and size of the primary tumour. These findings
are consistent with the study by Weinstein et al. (1991) who
found that expression of P-glycoprotein in colorectal car-
cinomas was independent of tumour size and histologic
grade. Weinstein et al. (1991), however, reported a higher
incidence of lymph node metastasis when P-glycoprotein
positive cells were present at the leading edge of the primary
tumour, suggesting that expression of P-glycoprotein is
associated with local tumour aggressiveness. In contrast, we
found no association between MDR1 RNA expression of the
primary tumour and tumour infiltration of the lymph nodes
or distant metastases (Table II). It should be noted, however,
that we have evaluated the MDR1 RNA levels of the tumour
specimens as a total and not only of specific areas within the
specimens.
Our results indicate that multidrug-resistant cells are pre-
sent in the carcinomas prior to any chemotherapy. The high
percentage of MDR1 RNA positive colorectal carcinomas
could, at least partly, account for the well known intrinsic
resistance of these tumours to anthracyclines and other drugs
transported by P-glycoprotein. MDR1 gene expression is
assumed to be involved also in the clinical drug resistance of
other malignant diseases (Bell et al., 1985; Gerlach et al., 1987;
Fojo et al., 1987b; Dalton et al., 1989; Goldstein et al., 1989;
Pirker et al., 1989; Chan et al., 1990; Wishart et al., 1990;
Pirker et al., 1991; Wallner et al., 1991. 1993). In neuroblas-
tomas (Chan et al., 1991), soft tissue sarcomas of childhood
(Chan et al., 1990) and adult acute myeloid leukemias (Pirker
et al., 1991; Marie et al., 1991; Campos et al., 1992), MDR1
gene expression of the malignant cells was associated with
shorter survival durations of the patients who had been
treated with protocols that included anthracyclines. In the
present study, we did not observe an impact of MDR1 gene
expression of the tumours on the durations of disease-free
survival and overall survival of the patients (Figures 2 and
3), indicating that MDR1 RNA expression of tumour speci-
mens is of no value for estimating prognosis. Whether P-
glycoprotein expression at the leading edge of the tumours, a
situation probably associated with a more aggressive disease
(Weinstein et al., 1991), might predict prognosis remains to
be determined. The lack of an association of MDRI RNA
expression with clinical outcome in our study can be
explained by several reasons. Firstly, the biological growth
behaviour of MDR1 RNA positive tumours might in fact
not be different from their negative counterparts. Secondly,
our patients were not treated with drugs that are affected by
the MDR1 gene. Response to 5-fluorouracil and leucovorin
should be independent of a functionally active MDR1 gene
because both drugs are not transported by P-glycoprotein.
Thirdly, we cannot exclude that the applied slot blot techni-
que contributed to the observed lack. Finally, longer follow-
up of our patients might demonstrate some impact of MDR1
RNA expression of the tumours on the long-term survival of
the patients.
Future studies will also have to address the impact of
MDR1 gene expression (of the primary or metastatic
tumour) on the resistance of the metastatic tumours to drugs
that are pumped by P-glycoprotein. If such an association
can be demonstrated, clinical trials with resistance modifiers
(Dalton et al., 1989; Pirker et al., 1990; Twentyman 1992)
might be warranted in patients with metastatic colorectal
carcinomas.
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